These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 12749508)

  • 1. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.
    Derosa G; Franzetti I; Gadaleta G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Jun; 17(3):143-50. PubMed ID: 15334791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
    Rizzo MR; Barbieri M; Grella R; Passariello N; Paolisso G
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):255-60. PubMed ID: 16142016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
    Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    Intern Med; 2007; 46(22):1837-46. PubMed ID: 18025765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
    Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Diabetes Res Clin Pract; 2003 Jun; 60(3):161-9. PubMed ID: 12757988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
    Rosenstock J; Samols E; Muchmore DB; Schneider J
    Diabetes Care; 1996 Nov; 19(11):1194-9. PubMed ID: 8908379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
    Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
    Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
    Anwar A; Azmi KN; Hamidon BB; Khalid BA
    Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.
    Cesur M; Corapcioglu D; Gursoy A; Gonen S; Ozduman M; Emral R; Uysal AR; Tonyukuk V; Yilmaz AE; Bayram F; Kamel N
    Diabetes Res Clin Pract; 2007 Feb; 75(2):141-7. PubMed ID: 16815586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.
    Sari R; Balci MK; Akbas SH; Avci B
    Endocr Res; 2004 May; 30(2):169-77. PubMed ID: 15473127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
    Landgraf R; Bilo HJ; Müller PG
    Eur J Clin Pharmacol; 1999 May; 55(3):165-71. PubMed ID: 10379630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.